The AstraZeneca human monoclonal antibody binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering a tumour’s immune-evading tactics.
News
Finalists announced for Marketer of the Year 2019
The finalists for the 2019 Marketer of the Year competition have now done all they can in their bid to be crowned the winner.
Number of NIHR-supported research participants exceeds 1M
The news marks a “significant milestone.”
NIHR, MRC buddy up to tackle global chronic disease
The organisations announced plans to invest over £6 million in five implementation science projects focused on tackling diabetes and hypertension in low- and middle-income countries.
AZ commits £28m to tackle non-communicable disease
The plan is designed to inform adolescents in under-resourced communities on how to reduce risky behaviours including smoking, alcohol, poor diet and lack of exercise.
Tecentriq, Avastin combo trumps Nexavar in liver cancer
Hepatocellular carcinoma is a major cause of cancer deaths worldwide, affecting over 750,000 people every year.
Gov’t announces social prescribing academy updates
Only 60% of CCGs use social prescribing for patients with anxiety, mental health problems and dementia, despite evidence that it helps.
Investigational gene therapy shows long-term success in AADC
There are currently no approved therapies that address the underlying cause of aromatic L-amino acid decarboxylase (AADC) deficiency.
‘Revolutionary’ liquid sickle cell treatment unveiled
The new formation will enable doctors to personalise doses for young children.
Xospata bags European Commission approval
The decision was based on the Phase III ADMIRAL trial, in which one-year survival rates shot to 37% for patients who received Xospata, compared to 17% for patients who received salvage chemotherapy.
First patient enrolled in Oxford BioDynamics’ ALS biomarker study
ALS – amyotrophic lateral sclerosis – is a specific disease that causes the death of neurons controlling voluntary muscles.
NHS review puts emphasis on vaccine uptake
One in seven five-year-olds may not be fully up to date with some routine immunisations, and the UK has lost its ‘measles-free’ status.
CR UK, Novartis, Sixth Element team up for hard to treat cancers
The collaboration focuses on the RAS family of genes, which cause more than 30% of all human cancers, including 95% of pancreatic cancers and 45% of colorectal cancers.
NHSE signs ‘definitive’ agreement for Vertex CF drugs
Even more excitingly, clinicians will be able to begin prescribing the drugs – Orkambi, Symkevi and Kalydeco – within just 30 days.
GPs call for ‘better training and tech’ for video consultations
Despite promising uptake figures, only 1% of all current consultations are delivered via video link.
